ArticleRespiratory research2026
S- nitrosylation of Annexin A2 at Cys133 ameliorates pulmonary arterial hypertension by inhibiting the WNT/β-catenin pathway.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe excessive proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), which result in pulmonary vascular remodeling, are crucial pathological features of pulmonary arterial hypertension (PAH). Protein S-nitrosylation (SNO), which is a modification by which a nitric oxide (NO) group is added to a cysteine residue, has been shown to play a critical role in PASMC proliferation and PAH, but the underlying mechanism remains largely unknown.
methodsUsing a combination of membrane and nuclear localization analyses, iodoTMT switch assays, molecular biology techniques, and in vitro and in vivo approaches, we investigated the effects of ANXA2 SNO at cysteine 133 (Cys133) on PASMC proliferation and migration in PAH.
resultsANXA2 protein expression was increased in PASMCs from rats with PAH. ANXA2 knockdown significantly inhibited excessive PASMC proliferation and migration. Additionally, inhibiting ANXA2 or conditionally knocking down ANXA2 in PASMCs ameliorated pulmonary vascular remodeling in experimental models of PAH. Moreover, we found that the NO donor S-nitrosoglutathione (GSNO) mediated the SNO of ANXA2 at Cys133 under hypoxic conditions. S-nitrosylated Cys133 (SNO-Cys133) of ANXA2 inhibited hypoxia-mediated PASMC proliferation and migration by regulating the subcellular localization of ANXA2 in cells. In addition, SNO-Cys133 of ANXA2 regulated the WNT pathway by inhibiting ANXA2 phosphorylation at Tyr24. Finally, SNO-Cys133 of ANXA2 ameliorated pulmonary vascular remodeling and improved RV function in vivo.
conclusionsSNO-Cys133 of ANXA2 suppressed ANXA2 relocation and the WNT pathway to ameliorate pulmonary vascular remodeling in PAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.